Global Exosome Research Products Market – Industry Trends and Forecast to 2030

Exosome Research Products Market Analysis and Insights

Increasing prevalence and incidences of cancer and various auto-immune diseases have enhanced the market demand. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in investments in pharmaceutical R&D and life sciences research also contributes to the rising demand for exosome research product testing.

The global exosome research products market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market.

Data Bridge Market Research analyzes that the global exosome research products market is expected to reach the value of USD 2,232,028.31 thousand by 2030, at a CAGR of 35.6% during the forecast period. Product accounts for the largest type segment in the market due to growing use of exosome research products in diagnostics and therapeutics.

Global Exosome Research Products Market Definition

The exosomes are a specific class of cell-derived extracellular vesicles composed of endosomes and are typically 30-150 nm in diameter – the smallest type of extracellular vesicle. Protected by a lipid bilayer, the exosomes are pushed into the extracellular environment, containing a complex cargo derived from the original cell. The contents present in the cargo are proteins, lipids, messenger ribonucleic acid (mRNA), microsomal ribonucleic acid (miRNA), and deoxyribonucleic acid (DNA).

The exosomes have been connected to treat various chronic conditions such as auto-immune disorders. Exosome therapeutics have been widely used in drug delivery, tumor immunotherapy, and diagnostic biomarkers. Exosomes are used as drug carriers due to their small size, native nature, and ability to cross biological barriers.

Global Exosome Research Products Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Growth in the prevalence of cancer, chronic inflammation, auto-immune disease, Lyme disease, and other chronic degenerative diseases

According to WHO, cancer is a top cause of death globally, accounting for approximately 10 million deaths in 2020. The number of cancer patients in India among males was around 679,421, and for females was almost 712,758 for the year 2020. The number of new cancer cases and deaths in 2021 was around 1.9 million, and 608,570 cancer deaths in the United States. Thus, cancer incidence is encouraging researchers to do more and more research, and biomarker is helpful in ide006Etifying cancer. Thus, the market growth is increased.

Thus, in conclusion, the rise in the number of chronic diseases such as cardiovascular diseases, neurological disorders, and various other chronic diseases has led to increased demand for various medicinal drugs and will drive the growth of the global exosome research products market in the coming years.

• Increase in investments in pharmaceutical R&D and life sciences research

Academic and research institutes, pharmaceutical and biotechnology businesses, hospitals, and clinical testing laboratories are the major end users of the market. There has been a rise in demand for exosome studies in recent years due to their potential in illness detection and their emerging role as intercellular messengers. This has attracted the interest of several academic researchers, leading to the market's growth. More than 6,000 items are currently being examined in clinical trials worldwide, representing a 68% increase over 2016, per the Pharmaceutical R&D spending trends in 2022.

As the market players are constantly engaged in research and developmental activities, more hybrid and natural exosomes are being introduced in the global exosome research products market. This would increase the demand for exosome therapeutics to treat cancer and auto-immune diseases in hospitals and diagnostic centers. Hence, the advancements in research and development activities and increasing investments in the pharmaceutical sector are expected to drive overall market growth.

Restraint

• Lack of gold standard protocols for the development and production of exosomes                                              

The field of exosomes is still at a nascent stage, and no gold standards have been developed so far. Thus the professionals employ new procedures and methodologies in the market without hesitation. In addition to researchers making mistakes during exosome production, scientists face various challenges in exosome research and development and manufacturing activities.

The lack of authentication and safety of the exosomes would hinder the safety protocols and the production of natural and hybrid exosomes. Hence, the lack of standard protocols in developing exosomes and the absence of authentication requirements for the isolation of exosomes are expected to restrain the growth of the exosome research products market.

Opportunity

• Rise in demand for specialized testing services among end users

Exosomes are small (30–150 nm) vesicles containing sophisticated RNA and protein cargo that are constantly secreted by all cells in vitro and in vivo. Exosomes are changing research due to the intriguing functions within the human body, including intercellular communication and signaling.

Henceforth, the rising use of specialized testing services such as liquid chromatography-mass spectrometry, RNA sequencing, wet chemistry, gene expressions, and various other testing services act as a driver for the growth of the exosome research product market and the ability of these testing services to provide accurate results with precision which has increased the demand among end users.

Challenge

• Side effects associated with exosome research products

While all medical treatments have benefits and risks, unapproved exosome products expose patients to potential risks without a clear benefit. These products may potentially treat many medical conditions and diseases, but further research is needed to know whether the products have any benefit or are safe to use. The side effects may include injection site reaction, failure of the cells to work as expected, growth of tumors, infections, and the potential for contamination of the product, the ability of cells to move from placement sites and multiply or change into inappropriate cell types

Henceforth, the various side effects of exosome research products for their diagnosis safety, cost, and convenience issues are expected to challenge the global exosome research products market.

Recent Developments

• In July 2022, Aethlon Medical, Inc., a medical therapy company focused on developing products for the diagnosis and treatment of cancer and life-threatening infectious diseases, announced that the US Food and Drug Administration (FDA) had approved a protocol amendment for an  ongoing clinical trial of Aethlon Hemopurifier for patients with severe COVID-19
• In April 2020, ExoDX launched the ExoDx Prostate Test Home Collection Kit for patients concerned about prostate health. The home collection kit provides an immediate and cost-effective solution that enables a telemedicine/telehealth option for physicians and their patients who share the frustration, anxiety, and fear of the advanced prostate cancer patient

Global Exosome Research Products Market Scope

Global exosome research products market is segmented into five notable segments such as product, indication, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY PRODUCT

• INSTRUMENTS
• Consumables

On the basis of product, the global exosome research products market is segmented into instruments and consumables.

GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY INDICATION

• CANCER
• NON CANCER

On the basis of indication, the global exosome research products market is segmented into cancer and non-cancer.

GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY APPLICATION

• THERAPEUTICS
• DIAGNOSTICS

On the basis of application, the global exosome research products market is segmented into therapeutics and diagnostics.

GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY END USERS

• HOSPITALS
• CLINICAL TESTING LABORATORIES
• RESEARCH CENTERS
• PHARMACEUTICAL AND BIOTECHNOLOGY COMPANY
• ACADEMIC INSTITUTES
• OTHERS

On the basis of end users, the global exosome research products market is segmented into hospitals, clinical testing laboratory, research centers, pharmaceutical and biotechnology company, academic institutes, and others.

GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY DISTRIBUTION CHANNEL

• THIRD PARTY DISTRIBUTORS
• ONLINE
• DIRECT TENDER

On the basis of distribution channel, the global exosome research products market is segmented into third party distributors, online, and direct tender.

Global Exosome Research Products Market Regional Analysis/Insights

The global exosome research products market is categorized into five notable segments such as product, indication, application, end user, and distribution channel.

The countries covered in this market report U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Sweden, Poland, Norway, Finland, Denmark, Belgium, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Bahrain, Kuwait, Oman, Qatar, and rest of Middle East and Africa.

North America is expected to dominate due to the presence of key market players in the largest consumer market with high GDP. The U.S is expected to grow due to the rise in technological advancement in exosome research products.

North America is expected to dominate the market due to the increasing investment in R&D is expected to boost the market growth. The U.S. dominates the North America region due to the strong presence of key players Hologic Inc., Luminex Corporation, and Thermo Fisher Scientific.

The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the market's current and future trends. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Exosome Research Products Market Share Analysis

Global exosome research products market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points only relate to the company's focus on the global exosome research products market.

Some of the major players operating in the global exosome research products market are Hologic Inc., Luminex Corporation, Thermo Fisher Scientific, Agilent Technologies, Inc., RoosterBio, Inc., Microgentas, Cell Guidance Systems LLC, QIAGEN, FUJIFILM Irvine Scientific (a subsidiary of FUJIFILM Holdings Corporation, CUSABIO TECHNOLOGY LLC, NEXOSOME-ONCOLOGY, Norgen Biotek Corp., Miltenyi Biotec, Aethlon Medical, Inc., System Biosciences, LLC., AMSBIO, ExoDx  (Acquired By Bio-Techne), BioVision Inc.  (Acquired By Abcam plc), HBMLS (Acquired by Lonza), Creative Bioarray, NanoSomiX, Novus Biologicals, Beckman Coulter, Inc. JSR Micro NV, Hitachi, Ltd., INOVIQ, ProteoGenex, and Audubon Bioscience, among others.

SKU-39642